David R. Soriano-Moreno

Mr. David R. Soriano-Moreno


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Healthcare Informatics Research
Verified
Journal Article
Open access
PDF file
KTKimberly G. Tuco
Kimberly G. Tuco
SCSharong D. Castro-Diaz
Sharong D. Castro-Diaz
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
VBVicente Aleixandre Benites-Zapata
Vicente Aleixandre Benites-Zapata
Objectives: The aim of this study was to assess the prevalence of nomophobia in university students.Methods: A systematic search was conducted of the following databases: Web of Science/ Core Collection, Scopus, PubMed, Embase, and Ovid/ MEDLINE until March 2021. Cross-sectional studies reporting the prevalence of nomophobia in undergraduate or postgraduate university students that assessed nomophobia with the 20-item Nomophobia Questionnaire (NMP-Q) tool were included. Study selection, data extraction, and risk of bias assessment were performed in duplicate. A meta-analysis of proportions was performed using a random-effects model. Heterogeneity was assessed using sensitivity analysis according to the risk of bias, and subgrouping by country, sex, and major.Results: We included 28 cross-sectional studies with a total of 11,300 participants from eight countries, of which 23 were included in the meta-analysis. The prevalence of mild nomophobia was 24% (95% confidence interval [CI], 20%–28%; I2 = 95.3%), that of moderate nomophobia was 56% (95% CI, 53%–60%; I2 = 91.2%), and that of severe nomophobia was 17% (95% CI, 15%–20%; I2 = 91.7%). Regarding countries, Indonesia had the highest prevalence of severe nomophobia (71%) and Germany had the lowest (3%). The prevalence was similar according to sex and major.Conclusions: We found a high prevalence of moderate and severe nomophobia in university students. Interventions are needed to prevent and treat this problem in educational institutions.

7 May 2023 in Health & Place
Verified
Journal Article
Closed access
FCFabricio Ccami-Bernal
Fabricio Ccami-Bernal
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
DGDaniel Fernandez Guzman
Daniel Fernandez Guzman
KTKimberly Grace Cabello Tuco
Kimberly Grace Cabello Tuco
SCSharong D. Castro-Díaz
Sharong D. Castro-Díaz
David Rojas-RuedaDavid Rojas-Rueda
David Rojas-Rueda

16 July 2022 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
JOJuan J. Olortegui-Rodriguez
Juan J. Olortegui-Rodriguez
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
ABAlejandro Benites-Bullón
Alejandro Benites-Bullón
PPPilar P. Pelayo-Luis
Pilar P. Pelayo-Luis
JHJorge Huaringa-Marcelo
Jorge Huaringa-Marcelo
Background: Chronic Obstructive Pulmonary Disease (COPD) remains one of the leading causes of morbidity and mortality worldwide, and its epidemiology in Latin America and the Caribbean is not well described. The aim of this study was to evaluate the prevalence and incidence of COPD in Latin America and the Caribbean. Methods: We searched systematically in Web of Science (WoS)/Core Collection, WoS/MEDLINE, WoS/Scielo, Scopus, PubMed, and Embase from 2010 to 2021. Studies assessing the prevalence and incidence of COPD according to the GOLD classification were included. The overall prevalence of COPD was calculated as a function of the general population using a random-effects model. Results: 20 studies (19 cross-sectional and 1 cohort) met the inclusion criteria. The prevalence of COPD in the general population older than 35 years was 8.9%. The prevalence in men was 13.7% and in women 6.7%. The prevalence in smokers and ex-smokers was 24.3%. The incidence in the general population of COPD according to one study was 3.4% at 9 years of follow-up. Conclusions: COPD is prevalent in Latin America, especially in men and in smokers and ex-smokers. Further prevalence and incidence studies in the general population are needed, as well as health policies and strategies to address the disease.

12 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Jose A. Gonzales ZamoraJose A. Gonzales Zamora
Jose A. Gonzales Zamora
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
ASAnderson Nelver Soriano-Moreno
Anderson Nelver Soriano-Moreno
LPLinda Ponce-Rosas
Linda Ponce-Rosas
Lucero Sangster-CarrascoLucero Sangster-Carrasco
Lucero Sangster-Carrasco
JAJorge Alave
Jorge Alave
Introduction: Due to the high incidence of mpox in Peru and the poor knowledge about this disease among healthcare workers in non-endemic countries, it is crucial to determine the knowledge status of Peruvian physicians. Methodology: We conducted an analytical cross-sectional study based on an online survey from August to September 2022. Physicians who had a medical license and lived and practiced medicine in Peru were included. To evaluate the factors associated with a higher level of knowledge, we used crude (cPR) and adjusted (aPR) prevalence ratios with 95% confidence intervals (95% CI) using Poisson regression. Results: We included 463 physicians. The mean age was 36.6 (SD: 10.3) years, and most were male (58.1%). Regarding knowledge, the median knowledge score was 14 [IQR: 13 to 15] out of 17 points. In terms of knowledge gaps, only 60.7% of the participants knew that there was an FDA-approved vaccine for mpox, 49.0% of participants knew about mpox proctitis and 33.3% acknowledged that it could be transmitted by the bite of an infected rodent. We found that taking care of patients with mpox (aPR: 1.39; 95% CI: 1.13 to 1.72) was associated with higher knowledge (>p50), while living in the eastern macro-region (aPR: 0.62; 95% CI: 0.42 to 0.93) was associated with lower knowledge (≤p50). Conclusions: Our study showed a high level of knowledge about mpox among Peruvian physicians. However, educational campaigns may be necessary, especially for physicians from the eastern region and those who do not have clinical experience with mpox.

27 April 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
GDGandy Dolores-Maldonado
Gandy Dolores-Maldonado
ABAlejandro Benites-Bullón
Alejandro Benites-Bullón
FCFabricio Ccami-Bernal
Fabricio Ccami-Bernal
DGDaniel Fernandez Guzman
Daniel Fernandez Guzman
ATAlvaro Taype-Rondan
Alvaro Taype-Rondan

12 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JZJ Pierre Zila-Velasque
J Pierre Zila-Velasque
DSDavid R. Soriano-Moreno
David R. Soriano-Moreno
SMSebastian A. Medina-Ramirez
Sebastian A. Medina-Ramirez
FCFabricio Ccami-Bernal
Fabricio Ccami-Bernal
SCSharong D Castro-Diaz
Sharong D Castro-Diaz
JZJessica Hanae Zafra-Tanaka
Jessica Hanae Zafra-Tanaka
Objective: The objective of this systematic review and meta-analysis was to assess the prevalence of hypertension in populations living at altitude in Latin America and the Caribbean. Methods: We conducted a systematic search from January 1, 2000 to January 10, 2023 in Web of Science (WoS)/Core Collection, WoS/Medline, WoS/Scielo, Scopus, PubMed and Embase databases. We included studies that assessed the prevalence of hypertension in altitude populations (>1500 m.a.s.l.) and these were meta-analyzed using a random-effects model. To assess the sources of heterogeneity, we performed subgroup and meta-regression analyses. Results: Thirty cross-sectional studies (117 406 participants) met the inclusion criteria. Studies used different cut-off points. The prevalence of hypertension in the studies that considered the cut-off point of ≥ 140/90 mmHg in the general population was 19.1%, ≥ 130/85 mmHg was 13.1%, and ≥ 130/80 mmHg was 43.4%. There was a tendency for the prevalence of hypertension to be higher in men. In meta-regression analyses, no association was found between altitude, mean age, year of publication, risk of bias and prevalence of hypertension. Conclusion: The prevalence of hypertension in the altitude population of Latin America and the Caribbean is lower than that reported in populations living at sea level and lower than other altitude populations such as Tibetans. PROSPERO: CRD42021275229.